cas: 71320-77-9 Moclobemide 4-Chloro-N-(2-morpholinoethyl)benzamide Moclobemide is the first of a new generation of non-hydrazine, reversible MAO-A inhibitors useful in the treatment of depression. Moclobemide is a selective inhibitor of MAO-A, allowing tyramine to be metabolized by MAO-B. In controlled studies, moclobemide was clinically superior to desipramine and showed no cholinergic or cardiovascular side-effects. A metabolite is currently under investigation for treatment of Parkinson's disease. Product Name: Moclobemide Synonyms: moclbemide;4-CHLORO-N[2-(4-MORPHOLINYL)ETHYL]-BENZAMIDE (MOCLOBEMIDE);Ro-11-1163, Aurorix, Manerix, Moclamine, p-Chloro-N-(2-morpholinoethyl)benzamide;MODOBEMDE;p-Chlor-N-(2-morpholinoethyl)benzamid;4-Chloro-(2-(4-morpholinyl)ethyl)benzamide;Moclobemide (base and/or unspecified salts);4-Chloro-N-[2-(4-morpholinyl)ethyl]benzamide, Aurorix, Moclamine CAS: 71320-77-9 MF: C13H17ClN2O2 MW: 268.74 Melting point: 137°C Boiling point: 447.7±40.0 °C Storage temp.: Room temp

cas: 137525-51-0 Pentadecapeptide BPC157 BPC-157 injection peptides BPC 157 is a gut peptide and possesses free radical scavenging activity. This peptide stimulates nitric oxide synthase generation and therefore offers gastric cytoprotection. Unlike other peptides, BPC 157 is effective without a carrier. It participates in muscle healing and is used in the treatment of gastrocnemius muscle complex. BPC 157 is a stable gastric pentadecapeptide that exhibit anti-ulcer and wounds/fistulas healing properties. BPC 157 reduces immediate and delayed damage induced brain trauma and improves nerve regeneration after transection. BPC 157 displays antianxiety and antidepressant effects. It appears that BPC 157 promotes proliferation, migration, and tube formation of human umbilical vein endothelial cells through activation of ERK1/2 phosphorylation. BPC-157 is characterized as a gastric pentadecapeptide that is shown to have had positive effects on the efficiency and efficacy of various growth hormones as well as various other healing qualities in cases such as spinal cord injury and burn wounds. BPC-157 Effects on Burn Healing A study conducted by Mikus et. Al examined the effects that treatment with BPC-157 had on mice that had experienced burns. They were treated with either an injection of BPC-157 or with a topical application of the peptide. Mice were put under anesthesia and were exposed to a flame for 5 seconds and given partial thickness skin burns over 20% of their bodies, either topical or intraperitoneal treatment with BPC-157 was administered immediately after the mice were burnt and every day thereafter until they were euthanized. For the intraperitoneal dosage 10 micrograms was administered to the rats and for the topical treatment a 50 microgram dosage mixed with 2 ml of water was applied to the burn. Overall it was found that when treating the burns with either an intraperitoneal injection or a topical cream of BPC-157 there was far more healing that occurred than the mice that were treated with a vehicle. The study concluded that by treating burns with the peptide there was less edema and fewer inflammatory cells. Additionally it was found that there was less necrosis in the burned portion of the skin, an increased number of capillaries, and more follicles that were able to be preserved BPC-157 Effects on Growth Hormone Receptors In a separate study, the effect BPC-157 has on the healing processes of various types of tissues was examined. Chang et. Al used male Sprague-Dawley and supplemented them with BPC-157 and isolated tendon fibroblasts in the achilles tendon. The study concluded that in a time-dependent and dose-dependent manner, supplementation with BPC-157 greatly increased the up-regulation of growth hormone. BPC-157 was given in doses of either 0, 0.1, 0.25, or 0.5 m